The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KLTO | -33.65% | N/A | N/A | -98% |
| S&P | +13.95% | +78.35% | +12.25% | +68% |
Anew Medical, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It operates through the following segments: Generic Drugs, Gene Therapy, and Pharmaceutical Programs. The Generic Drugs segment consists of portfolio of drugs and biosimilar biologics selling hard-to-source, difficult to find generic drugs and off-patent biologic therapies, and proprietary and patented technology platforms that include a library of melanocortin receptor-binding molecules. The Gene Therapy segment focuses on the gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging. The Pharmaceutical Programs segment includes treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The company was founded on August 2, 2004 and is headquartered in Omaha, NE.
No news articles found for Klotho Neurosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $29.74M | 113.7% |
| Market Cap / Employee | $9.91M | 0.0% |
| Employees | 3 | 0.0% |
| Net Income | -$2,895.59K | 2.2% |
| EBITDA | -$1,853.30K | 35.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.35M | 14337.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -180.10% | -168.7% |
| Return On Invested Capital | -135.38% | -172.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,088.21K | -1.4% |
| Operating Free Cash Flow | -$1,088.21K | -1.4% |
| Metric | Q1 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1344.94 | - | |||
| Price to Book | 6.60 | 5.20 | 50.45 | 2.40 | -136.26% |
| Price to Tangible Book Value | -11.35 | -5.53 | -19.40 | 3.06 | -215.06% |
| Enterprise Value to EBITDA | -7.21 | -4.70 | -15.81 | -11.57 | 201.37% |
| Return on Equity | -90.4% | -131.5% | -249.6% | -198.3% | 1403.04% |
| Total Debt | $271.75K | $1.77M | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
